It is an achievement worthy of note and very encouraging.
At this stage of the company growth cycle I believe Admedus/WP is somewhat concerned with being overly transparent around their progress due to the competitive nature of the market. That is also why ADAPT sales are most likely not split by product.
This does suck for us shareholders at the current SP but it's a long game for me so as long as this manifests in revenue/profits I'm not too worried.
While account openings are great, it is revenue growth that will ultimately drive the share price
Professor Neethling named VP of Cardiovascular Technologies, page-14
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.76 |
Change
0.000(0.00%) |
Mkt cap ! $248.1M | |||
| Open | High | Low | Value | Volume |
| $11.98 | $12.00 | $11.51 | $95.19K | 8.067K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28 | $12.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.18 | 79 | 1 |
View Market Depth
| Last trade - 15.59pm 08/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |